Alphabet Soup Progressing Under Cancer Treatment

A cutting-edge cancer treatment has helped reduce skin cancer in 1996 Breeders' Cup Classic (G1) winner Alphabet Soup, who recently celebrated his 26th birthday at Old Friends Equine retirement home near Georgetown, Ky.

The cancer treatment is a vaccine that allows Alphabet Soup's immune system to target the melanoma. Since skin cancer cells were first collected in mid-July for use in developing the vaccine and eight treatments that followed, veterinarian Dr. Bryan Waldridge, of Park Equine Hospital, has seen a reduction between 75% and 80% in the cancerous masses that had developed near his tail.

"We're hoping the immune system will stay after that cancer. We're hoping for a progressive shrinkage," Waldridge said. "I would think it would be months in the future until we know where we're going to get to, but it's gone down enough that I wouldn't be shocked to see this totally go away." 

Old Friends founder Michael Blowen has seen Alphabet Soup in better spirits in the paddocks as the treatment has reduced the cancer. The treatment is being funded by the son of Cozzene's former residence at stud, Frank Stronach's Adena Springs.

The IFx-VET multi-indication cancer vaccine allows the retired stallion's immune system to target and eliminate cancer cells by placing an indicator on the cancer cells to alert the immune system of the enemy. Besides being effective, it has the added advantage of being less invasive compared with some other treatments.

Read More: Promising Cancer Treatment for an Old Friend

After the vaccine was developed, Alphabet Soup received one treatment a week for four straight weeks and then one treatment a month for four straight months; a total of eight treatments. The final treatment was administered earlier this month. Waldridge has taken pictures of the masses throughout that time which have documented the progress.

"I would be thrilled to stay where we are and we're even ahead of where I ever thought we would be," Waldridge said. "I guess we can figure continued shrinkage of the masses being our best-case scenario."

Waldridge said he's had several other veterinarians ask about the treatment and he said he can't speak highly enough of the service provided through Veterinary Oncology Services-Morphogenesis.

In a print edition feature in BloodHorse, Patricia Lawman, chief executive officer of treatment developer Morphogenesis, said even though her company has been on the front line, the treatment sometimes still amazes her.

"For so many people it sounds too good to be true being able to treat these cancers with no side effects and relatively little money...but that's what this technology is and how it works," Lawman said. "It's not specific to any tumor because it's a bacteria that can be injected into any tumor, and it doesn't cause side effects." 

Steve Hazell, director of business development for Veterinary Oncology Services-Morphogenesis, believes the ideas behind the treatment can be used on many different cancers. The company also hopes to expand into treating people.